Free Trial
NASDAQ:REPL

Replimune Group Q4 2026 Earnings Results & Report

Replimune Group logo
$21.78 -1.50 (-6.44%)
Closing price 11/11/2026 04:00 PM Eastern
Extended Trading
$21.74 -0.04 (-0.16%)
As of 11/11/2026 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Replimune Group missed analyst earnings expectations in its Q4 2026 results, released June 29, 2026. The company reported EPS of -$0.76 versus the -$0.6613 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2026
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

Replimune Group EPS Results

Actual EPS
-$0.76
Consensus EPS
-$0.6613
Beat/Miss
Missed by -$0.0988
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

Replimune Group Revenue Results

Actual Revenue
N/A
Expected Revenue
$3.57 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Replimune Group Q4 2026 Earnings FAQ

Replimune Group (NASDAQ:REPL) reported earnings of -$0.76 per share for Q4 2026, missing the consensus estimate of -$0.6613. The report was announced on Monday, June 29, 2026.

Replimune Group Earnings Headlines

Short Interest Powder Kegs: 10 Stocks Bears Cannot Quit Buying
Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
Cramer's lightning round: Buy FedEx Freight
See More Replimune Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Replimune Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Replimune Group and other key companies, straight to your email.

About Replimune Group

Replimune Group (NASDAQ:REPL) is a biotechnology company focused on developing tumor-directed immunotherapies for people with cancer. Its proprietary platform uses genetically modified herpes simplex viruses, designed to be injected into tumors and stimulate an immune response against cancer.

The company’s investigational pipeline includes RP1, an engineered oncolytic virus that expresses proteins intended to promote tumor cell destruction and immune activation. Replimune is also developing other candidates that combine virus-based treatment with additional immune-stimulating approaches. These programs remain investigational and are being evaluated in clinical studies.

Founded in 2015, Replimune is headquartered in Woburn, Massachusetts. Its work centers on research and clinical development rather than marketed products or services.

View Replimune Group Profile